FindTrial
Sign In

Clinical efficacy of taijiquan combined with huanshao dan in mild Alzheimer's disease with deficiency of spleen and kidney

Effect evaluation and mechanism study of non pharmacological therapy combined with Huanshaodan on mild cognitive impairment and mild to moderate Alzheimer's disease with spleen and kidney deficiency in older adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080046
Enrollment
Unknown
Registered
2024-01-18
Start date
2023-04-06
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Taijiquan Group:tai chi exercise
Return to the young Dan group:Oral rejuvenating pills
Tai Chi combined with Huanshao Dan:Taijiquan exercise + oral rejuvenation medicine
Control group:None

Sponsors

Chengdu Eighth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age = 60 years 2. Meet the diagnostic criteria for mild to moderate Alzheimer's disease with spleen and kidney deficiency : referring to the core clinical standards for AD dementia developed by the National Institute of Aging (NIA) and the Alzheimer's Association (AA) in the United States, the diagnosis is highly likely to be AD; Progressive memory or other cognitive impairment for = 3 months; MMSE score of the Simplified Mental State Scale: Illiteracy = 19 points; Primary school = 22 points, secondary school and above = 24 points; Clinical dementia rating (CDR) score = 1 point; Daily living ability ADL (14 items) score = 17 points; Using the Dementia Syndrome Classification Scale (SDSD) to screen AD patients with spleen and kidney deficiency; 3. willing to accept to cooperate with the implementation of the study 4. Length of stay expected to be = three months.

Exclusion criteria

Exclusion criteria: 1. cognitive decline due to intracranial pathology or with other neurological disorders (e.g. Parkinson's, stroke, etc.) 2. who are currently undergoing cognitive therapy 3. having a chronic disease that prevents movement; 4. those who have hypertension and whose blood pressure cannot be controlled 5. those with visual and hearing impairment and communication difficulties 6. who are participating in other research trials that affect the results of this study 7. those with severe sleep disorders, anxiety and depression.

Design outcomes

Primary

MeasureTime frame
memory function;executive function;cognitive function;cognitive function;cognitive function;—

Secondary

MeasureTime frame
health status;sleep condition;emotional state;—

Countries

China

Contacts

Public ContactLin Lin

Chengdu Eighth People's Hospital

16linlin@163.com+86 136 8811 9536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026